Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor

Hiltermann, T Jeroen N; Pore, Milind; Berg, Anke van den; Timens, Wim; Boezen, H. Marike; Liesker, Jeroen J W; Schouwink, J.H.; Wijnands, W. J. A.; Kerner, Gerald S. M. A.; Kruyt, Frank A.E.; Tissing, H.; Tibbe, Arjan G.J.; Terstappen, Leon W.M.M.; Groen, Harry J.M.

doi:10.1093/annonc/mds138

Cited by 194 publications

(195 citation statements)

References 28 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…For example, in SCLC the total numbers of CTCs were significantly decreased following a single dose of chemotherapy (166,167). Similar results were observed in patients with NSCLC (5,(168)(169)(170).…”

Section: Treatment Response and Mechanisms Of Resistancesupporting

confidence: 69%

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Mohan¹,

Chemi²,

Brady³

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Section: Treatment Response and Mechanisms Of Resistancesupporting

confidence: 69%

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Mohan¹,

Chemi²,

Brady³

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

“…A reduction of CTC count exceeding 89% in response to chemotherapy was associated with a lower risk of death (HR =0.24; 95% CI, 0.09-0.61). Similarly, lower numbers of CTCs were observed for 21 patients with LD-SCLC (median =6; range, 0-220) compared with 38 patients with ED-SCLC (median =63; range, 0-14,040) and the absence of CTCs in 27% of patients was correlated with prolonged survival (HR =3.4; P≤0.001) (62).…”

Section: Sclc and Ctcsmentioning

confidence: 79%

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Hamilton¹,

Rath²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

CTCs. SCLC has an unfavorable prognosis due to rapid dissemination and early chemoresistant relapses. SCLC CTCs recruit macrophages and elicit secretion of various cytokines and the six CTC lines expresschitinase-3-like-1 (CHI3L1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP9) in abundance. CHI3L1 is cytokine/growth factor expressed in inflammation and cancer and found to be correlated to metastasis and a dismal prognosis. In conclusion, SCLC CTCs have acquired the essential means for aggressiveness and invasion in a tumor microenvironment specifically shaped by macrophages and inflammation.

show abstract

“…Indeed, a O33% higher number of CTC, measured after 3-5 weeks of treatment, was associated with poorer PFS and OS (respective HR, 23.1 and 18.9) compared with no increase (Khan et al 2012). Whether serial CTC determinations could be relevant for NET follow-up and a potential surrogate of therapeutic response requires further investigation in specific clinical trials, as shown for other malignancies (Matsusaka et al 2010, Danila et al 2011, Hiltermann et al 2012, Boutrus et al 2013. However, the main limitations of using CTC in routine practice are the limited availability and non-standardization of their measurement technique.…”

Section: Biological Markers Tumor Progression and Therapeutic Respomentioning

confidence: 99%

Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art

Mestier¹,

Dromain²,

d’Assignies³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Well-differentiated neuroendocrine tumors (NETs) are a group of heterogeneous rare tumors. They are often slow-growing and patients can have very long survival, even at the metastatic stage. The evaluation of tumor progression and therapeutic responses is currently based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST) criteria. As for other malignancies, RECIST criteria are being reexamined for NETs in the era of targeted therapies because tumor response to targeted therapies is rarely associated with shrinkage, as opposed to prolonged progression-free survival. Therefore, size-based criteria no longer seem to be suitable to the assessment of NET progression and therapeutic responses, especially considering targeted therapies. New imaging criteria, combining morphological and functional techniques, have proven relevant for other malignancies treated with targeted therapies. To date, such studies have rarely been conducted on NETs. Moreover, optimizing the management of NET patients also requires considering clinical, biological, and pathological aspects of tumor evolution. Our objectives herein were to comprehensively review current knowledge on the assessment of tumor progression and early prediction of therapeutic responses and to broaden the outlook on well-differentiated NETs, in the era of targeted therapies.

show abstract

Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor

Cited by 194 publications

References 28 publications

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art

Contact Info

Product

Resources

About